Undifferentiated Connective-Tissue Disease 

  • Author: Bernard Hildebrand, MD; Chief Editor: Herbert S Diamond, MD   more...
 
Updated: Jan 19, 2012
 

Background

Connective-tissue diseases (CTDs) manifest with a wide range of clinical findings and laboratory abnormalities. The diversity of signs and symptoms frequently complicates the diagnosis of a rheumatic disease.

Diagnostic and classification criteria have been established for many CTDs, including rheumatoid arthritis (RA),[1] systemic lupus erythematosus (SLE),[2, 3] systemic sclerosis (SSc),[4] polymyositis (PM), dermatomyositis (DM),[5] mixed connective-tissue disease (MCTD),[6] and Sjögren syndrome (SS).[7, 8]

Some of these disease criteria overlap, further complicating the diagnostic workup in patients with a potential CTD. Unclassifiable symptoms, physical examination findings, or serological results suggestive of a CTD frequently lead to diagnoses such as incomplete lupus, latent lupus, overlap syndrome, and undifferentiated connective-tissue disease (UCTD). Conceptually, these terms may seem synonymous; however, specific definitions are necessary for appropriate diagnostic, therapeutic, and prognostic determinations.

In 1980, LeRoy et al proposed the concept of undifferentiated connective-tissue syndromes (UCTS) to characterize mixed or overlapping syndromes.[9] Since that time, innumerable case reports, case series, and clinical studies have used variable criteria to define UCTD. Such variation in the definition of UCTD results in ambiguity of study results and difficulty with interpreting the findings and conclusions. In 1999, Mosca et al proposed preliminary classification criteria for UCTD that have become increasingly accepted and used.[10] The authors suggested defining cases of UCTD as those in which signs and symptoms are consistent with a CTD but that do not fulfill the classification or diagnostic criteria for any one of the defined CTDs (ie, RA, SLE, SSc, PM/DM, MCTD, SS). In order to fulfill the criteria for UCTD, antinuclear antibodies must be present, along with a disease duration of at least 3 years. Cases with a shorter duration should be described as early UCTD.

Other definitions for UCTD have been proposed.[9, 11, 12, 13, 14, 15, 16, 17] However, many of these definitions are limited by the fact that they may lead to the inclusion of a defined CTD manifesting early or in an incomplete form. In 2008, Mosca et al admitted that, while their proposed classification criteria exclude most patients with an evolving definite CTD, limitations are evident. Their criteria do not allow the diagnosis of UCTD to be made at onset. In addition, the criteria do not exclude a slowly evolving or an incomplete definite CTD.[18] To avoid the misdiagnosis of transitory or early defined CTD, exclusion criteria were appended to the proposed classification criteria above.[19] These preliminary classification criteria for UCTD are listed in Table 1, although no mutual agreement has been reached regarding the criteria for diagnosis of UCTD.[20]

Table 1. Preliminary Classification Criteria for Undifferentiated Connective-Tissue Disease (Open Table in a new window)

Inclusion CriteriaClinical



Exclusion Criteriaa



Laboratory Exclusion Criteriaa
1. Signs and symptoms suggestive of a CTD but not fulfilling the diagnostic or classification criteria for any of the defined CTDs b for at least 3 years c



2. Presence of antinuclear antibodies determined on two different occasions



Malar rash



Subacute cutaneous lupus



Discoid lupus



Cutaneous sclerosis



Heliotrope rash



Gottron papules



Erosive arthritis



Anti-dsDNA



Anti-Smith



Anti-U1-RNP



Anti-Scl70



Anticentromere



Anti-La/SSB



Anti-Jo1



Anti-Mi2



a Applicable to patients at disease onset

b Using established classification criteria for SLE, MCTD, SSc, PM/DM, RA and SS

c If the disease duration is less than 3 years, patients may be defined as having an early UCTD.

Adapted from Mosca et al[10] and Doria et al[19]

Next

Pathophysiology

As with all the CTDs, the etiology of UCTD is unknown, and the lack of validated classification criteria has complicated the task of elucidating the pathophysiology. Generally, autoimmune diseases, including UCTD, are believed to exist in different phases.[21, 22]

The initial phase may occur many years prior to diagnosis, during which time the patient may be asymptomatic and may lack serum autoantibodies. Currently, patients with autoimmune disease are believed to have a genetic predisposition. In the second phase, autoantibodies may appear in the serum despite an absence or paucity of symptoms. The interval between autoantibody appearance and significant symptom onset is highly variable among individual patients and the specific autoantibodies. Finally, signs and symptoms of the autoimmune disease appear, leading to a definitive diagnosis. Environmental factors likely trigger the onset of this final stage. A clinical diagnosis of early UCTD[10] may be made in the second phase, and some of these cases may evolve into a definite CTD or may remain undifferentiated.

UCTD has been associated with numerous autoantibodies, but whether these autoantibodies are etiopathogenic or simply markers of the disease is unknown. Specific autoantibodies to HSP60, HSP65, and transcription factor Sp1 were identified in patients with UCTD and proposed to be pathogenic; however, further research is necessary to clarify this issue.[23, 24]

Research is being directed to evaluate disease features that may delineate the evolution of UCTD. In 2008, Szodoray et al assessed whether abnormalities in the distribution of various immune-competent T-cell populations exist in patients with UCTD and whether certain immune phenotypes predict subsequent development of defined CTDs.[25] The relative and absolute number of natural regulatory T cells (Tregs) decreased in patients with UCTD when compared with controls. In the patients who developed a definite CTD, the number of natural Tregs was further decreased, suggesting that patients with lower numbers of Treg cell subsets may be more likely to develop a definite CTD.

Furthermore, it has been proposed that vitamin D deficiency may contribute to pathological changes in the number and function of CD4+ T-helper cell subsets in patients with UCTD, and vitamin D supplementation may improve the fine balance of proinflammatory and antiinflammatory processes in the disease.[26]

Previous
Next

Epidemiology

Frequency

International

No epidemiologic studies have been completed for UCTD, and disease prevalence can be estimated only by extrapolating data from small case series. Mosca et al (1999) note that 20%-52% of patients in rheumatology clinics with a CTD may have UCTD.[10] This wide range is attributable to varying selection criteria. Disease duration of less than one year may result in transient disease or early-defined CTD being classified as UCTD.

Guerrero et al conducted a similar study of 94 patients over 12 months in Colombia. They concluded that arthritis, Raynaud phenomenon, and the presence of photosensitivity were predictors for the development of CTD. A consensus is required to establish criteria for the classification of UCTD.[27]

Mortality/Morbidity

UCTD may evolve into a defined CTD in 20%-40% of patients, and 50%-60% remain undifferentiated.[18] Ten to 20% percent of patients have symptoms that eventually subside and never evolve into a defined CTD.[25] The likelihood of evolution to a defined CTD is highest during the first 3-5 years of the disease,[28] and the rate of evolution continues to decrease thereafter.[29] Patients who develop a defined CTD late have been noted to have milder disease with a lower incidence of serious adverse events and a good prognosis.[15, 29]

In contrast to the defined CTDs, UCTD is characterized by a mild clinical picture. However, exceptions are notable, as UCTD has been associated with severe, organ-involving, and life-threatening complications, including thrombotic thrombocytopenic purpura,[30] myocarditis,[31] nonspecific interstitial pneumonia,[32] cardiovascular disease,[33] vasculitis,[34] cardiac tamponade,[35] and hepatic injury.[36] Survival rates associated with UCTD are similar to those associated with RA and SLE.[37]

Race

One study in the United States reported 72% of patients with UCTD were white.[38] Two Italian studies[11, 29] and a Hungarian study[15] did not report the racial characteristics of UCTD cases. Racial prevalence is still uncertain given the limited available data and possible selection bias introduced in those studies.

Sex

As with many other autoimmune CTDs, UCTD is much more likely to be diagnosed in females. In the United States, 78% of UCTD diagnoses are in females,[38] 93%-95% in Italy,[11, 29] and 94% in Hungary[15] .

Age

UCTD is typically diagnosed in patients in the 3rd to 5th decade of life. However, pediatric and elderly-onset cases have been reported.[38] Patients with SLE who have a prior history of UCTD are diagnosed with SLE approximately 6 years later than patients with SLE who do not have a prior history of UCTD.[15]

Previous
Proceed to Clinical Presentation
 
 
Contributor Information and Disclosures
Author

Bernard Hildebrand, MD  Chief of Rheumatology, Mike O'Callaghan Federal Hospital, Nellis Air Force Base

Bernard Hildebrand, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, and American Society for Bioethics and Humanities

Disclosure: Nothing to disclose.

Coauthor(s)

Daniel F Battafarano, DO, FACP, FACR  Clinical Professor of Medicine, University of Texas Health Science Center at San Antonio; Associate Professor of Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Chief of Rheumatology Service, San Antonio Military Medical Center

Daniel F Battafarano, DO, FACP, FACR is a member of the following medical societies: American College of Physicians, American College of Rheumatology, and Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Elliot Goldberg, MD  Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Temple University School of Medicine

Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, and American College of Rheumatology

Disclosure: Nothing to disclose.

Alex J Mechaber, MD, FACP  Senior Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine

Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD  Adjunct Professor of Medicine, Division of Rheumatology, University of Pittsburgh School of Medicine; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, and Phi Beta Kappa

Disclosure: Merck Ownership interest Other; Smith Kline Ownership interest Other; Zimmer Ownership interest Other

References

  1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. Mar 1988;31(3):315-24. [Medline].

  2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. Nov 1982;25(11):1271-7. [Medline].

  3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. Sep 1997;40(9):1725. [Medline].

  4. American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. May 1980;23(5):581-90. [Medline].

  5. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. Feb 13 1975;292(7):344-7. [Medline].

  6. Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol. Mar 1989;16(3):328-34. [Medline].

  7. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. Mar 1993;36(3):340-7. [Medline].

  8. Fox RI, Saito I. Criteria for diagnosis of Sjogren's syndrome. Rheum Dis Clin North Am. May 1994;20(2):391-407. [Medline].

  9. LeRoy EC, Maricq HR, Kahaleh MB. Undifferentiated connective tissue syndromes. Arthritis Rheum. Mar 1980;23(3):341-3. [Medline].

  10. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. Sep-Oct 1999;17(5):615-20. [Medline].

  11. Danieli MG, Fraticelli P, Franceschini F, et al. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol. Sep-Oct 1999;17(5):585-91. [Medline].

  12. Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Intern Med. Nov 1989;149(11):2473-6. [Medline].

  13. Ganczarczyk L, Urowitz MB, Gladman DD. "Latent lupus". J Rheumatol. Apr 1989;16(4):475-8. [Medline].

  14. Swaak AJ, van de Brink H, Smeenk RJ, Manger K, Kalden JR, Tosi S. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford). Jan 2001;40(1):89-94. [Medline].

  15. Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. May-Jun 2003;21(3):313-20. [Medline].

  16. Cavazzana I, Franceschini F, Belfiore N, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol. Jul-Aug 2001;19(4):403-9. [Medline].

  17. Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. Aug 2009;28(8):915-21. [Medline].

  18. Mosca M, Tani C, Bombardieri S. A case of undifferentiated connective tissue disease: is it a distinct clinical entity?. Nat Clin Pract Rheumatol. Jun 2008;4(6):328-32. [Medline].

  19. Doria A, Mosca M, Gambari PF, Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both?. J Rheumatol. Feb 2005;32(2):213-5. [Medline].

  20. Conti V, Esposito A, Cagliuso M, Fantauzzi A, Pastori D, Mezzaroma I. Undifferentiated connective tissue disease - an unsolved problem:revision of literature and case studies. Int J Immunopathol Pharmacol. Jan-Mar 2010;23(1):271-8. [Medline].

  21. Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases?. Arthritis Rheum. Jun 2007;56(6):1736-44. [Medline].

  22. Cappelli S, Bellando Randone S, Martinovic D, Tamas MM, Pasalic K, Allanore Y, et al. "To Be or Not To Be," Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. Semin Arthritis Rheum. Sep 27 2011;[Medline].

  23. Horvath L, Czirjak L, Fekete B, et al. Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol Lett. Jan 1 2001;75(2):103-9. [Medline].

  24. Spain TA, Sun R, Gradzka M, et al. The transcriptional activator Sp1, a novel autoantigen. Arthritis Rheum. Jun 1997;40(6):1085-95. [Medline].

  25. Szodoray P, Nakken B, Barath S, Gaal J, Aleksza M, Zeher M. Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease. Int Immunol. Aug 2008;20(8):971-9. [Medline].

  26. Zold E, Szodoray P, Nakken B, Barath S, Kappelmayer J, Csathy L, et al. Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. Autoimmun Rev. Jan 2011;10(3):155-62. [Medline].

  27. Guerrero LF, Rueda JC, Arciniegas R, Rueda JM. Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. Rheumatol Int. Nov 25 2011;[Medline].

  28. Mosca M, Tani C, Bombardieri S. Defining undifferentiated connective tissue diseases: a challenge for rheumatologists. Lupus. 2008;17(4):278-80. [Medline].

  29. Mosca M, Neri R, Bencivelli W, Tavoni A, Bombardieri S. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol. Nov 2002;29(11):2345-9. [Medline].

  30. Gupta D, Roppelt H, Bowers B, Kunz D, Natarajan M, Gruber B. Successful remission of thrombotic thrombocytopenic purpura with rituximab in a patient with undifferentiated connective tissue disorder. J Clin Rheumatol. Apr 2008;14(2):94-6. [Medline].

  31. Martorell EA, Hong C, Rust DW, Salomon RN, Krishnamani R, Patel AR. A 32-year-old woman with arthralgias and severe hypotension. Arthritis Rheum. Nov 15 2008;59(11):1670-5. [Medline].

  32. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. Am J Respir Crit Care Med. Oct 1 2007;176(7):691-7. [Medline].

  33. Deng XL, Liu XY. Comparative Study of 181 Cases of Diffuse Connective Tissue Disease Complicated by Cardiovascular Disease. International Journal of Rheumatic Diseases. Nov 2008;11 (Suppl. 1):A462.

  34. Oh CW, Lee SH, Heo EP. A case suggesting lymphocytic vasculitis as a presenting sign of early undifferentiated connective tissue disease. Am J Dermatopathol. Oct 2003;25(5):423-7. [Medline].

  35. Oishi Y, Arai M, Kiraku J, Doi H, Uchiyama T, Hasegawa A. Unclassified connective tissue disease presenting as cardiac tamponade: a case report. Jpn Circ J. Aug 2000;64(8):619-22. [Medline].

  36. Zhang Y, Zhang FK, Wu XN, Wang TL, Jia JD, Wang BE. Undifferentiated connective tissue diseases-related hepatic injury. World J Gastroenterol. May 7 2008;14(17):2780-2. [Medline].

  37. Williams HJ, Alarcon GS, Joks R, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol. Apr 1999;26(4):816-25. [Medline].

  38. Alarcón GS, Williams GV, Singer JZ, Steen VD, Clegg DO, Paulus HE. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol. Sep 1991;18(9):1332-9. [Medline].

  39. Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol. 1998;17(3):195-201. [Medline].

  40. Calvo-Alen J, Alarcon GS, Burgard SL, et al. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol. Mar 1996;23(3):469-75. [Medline].

  41. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. Jul 2007;56(7):2344-51. [Medline].

  42. Mosca M, Baldini C, Bombardieri S. Undifferentiated connective tissue diseases in 2004. Clin Exp Rheumatol. Jan-Feb 2004;17(5):22(3 Suppl 33). [Medline].

  43. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. Aug 2010;69(8):1420-2. [Medline].

  44. Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D, Manoni F, et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol. Feb 2002;117(2):316-24. [Medline].

  45. Ceribelli A, Cavazzana I, Franceschini F, Quinzanini M, Rizzini FL, Cattaneo R. Isotype switching and titer variation of anti-Ro/SSA antibodies over time in 100 patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. Jan-Feb 2008;26(1):117-20. [Medline].

  46. Zold E, Szodoray P, Gaal J, Kappelmayer J, Csathy L, Gyimesi E. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther. 2008;10(5):R123. [Medline].

  47. Cortes S, Clemente-Coelho P. [Nailfold capillaroscopy in the evaluation of Raynaud's phenomenon and undifferentiated connective tissue disease]. Acta Reumatol Port. Apr-Jun 2008;33(2):203-9. [Medline].

  48. [Best Evidence] Spinillo A, Beneventi F, Epis OM, Montanari L, Mammoliti D, Ramoni V. The effect of newly diagnosed undifferentiated connective tissue disease on pregnancy outcome. Am J Obstet Gynecol. Dec 2008;199(6):632.e1-6. [Medline].

 
Previous
Next
 
Table 1. Preliminary Classification Criteria for Undifferentiated Connective-Tissue Disease
Inclusion CriteriaClinical



Exclusion Criteriaa



Laboratory Exclusion Criteriaa
1. Signs and symptoms suggestive of a CTD but not fulfilling the diagnostic or classification criteria for any of the defined CTDs b for at least 3 years c



2. Presence of antinuclear antibodies determined on two different occasions



Malar rash



Subacute cutaneous lupus



Discoid lupus



Cutaneous sclerosis



Heliotrope rash



Gottron papules



Erosive arthritis



Anti-dsDNA



Anti-Smith



Anti-U1-RNP



Anti-Scl70



Anticentromere



Anti-La/SSB



Anti-Jo1



Anti-Mi2



Table 2. Predictors of Progression to Definite Connective-Tissue Disease
Connective-Tissue Disease AssociationSigns or SymptomsLaboratory Data
Systemic lupus erythematosusAge, fever, photosensitivity, serositis, alopeciaANA, Anti-dsDNA, Anti-Smith, Anti-cardiolipin antibodies, Coombs positivity, leukopenia
Systemic sclerosisSclerodactyly, Raynaud phenomenon, sicca symptoms, esophageal dysfunctionANA with nucleolar pattern
Sjögren syndromeXerostomia, xerophthalmia, Raynaud phenomenonAnti-SSA, Anti-SSB
Rheumatoid arthritisSymmetric polyarthritisRF, elevated ESR (>70 mm/h)
Mixed connective-tissue diseaseEsophageal reflux, polyarthritis, Raynaud phenomenonANA, Anti-U1-RNP
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.